A Phase 1 interventional study of Omaveloxolone in Healthy Volunteer, sponsored by Biogen. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-22.
Sponsored by Biogen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, researchers will learn how BIIB141, also known as omaveloxolone or SKYCLARYS®, moves through the body. This is a drug available for doctors to prescribe for patients with Friedrich's Ataxia. But, this drug has not yet been tested in women who have recently given birth and are breastfeeding or pumping milk for their babies. So, researchers do not know how much of the drug could be passed on to babies through the breastmilk of mothers who may take BIIB141.
The main objective of this study is to learn how a single dose of BIIB141 is processed in both the breastmilk and in the blood of healthy women who are breastfeeding.
The main question researchers want to answer in this study is:
Researchers will also learn more about:
This study will be done as follows:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of omaveloxolone on Day 1.
Drug: Omaveloxolone
Administered as specified in the treatment arm.
Also known as: BIIB141, SKYCLARYS
Maximum Observed Concentration (Cmax) of Omaveloxolone in Breast Milk
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Time to Achieve Cmax (Tmax) of Omaveloxolone in Breast Milk
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Average Concentration Based on Area Under the Concentration-Time Curve (AUC [Cav]) of Omaveloxolone in Breast Milk
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Area Under the Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-tlast) of Omaveloxolone in Breast Milk
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Time of the Last Measurable Concentration (Tlast) of Omaveloxolone in Breast milk
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
AUC Time Curve From Time Zero to Infinity (AUCinf) of Omaveloxolone in Breast Milk
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Milk-to-Plasma Ratio (M/P) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Cumulative Amount of Omaveloxolone Excreted in Breast Milk (Ae) Over 24 Hours (Ae0-24) Postdose
Time frame: At multiple timepoints postdose (up to 24 hours)
Cumulative Amount of Omaveloxolone Excreted in Breast Milk (Ae) Over 96 Hours (Ae0-96) Postdose
Time frame: At multiple timepoints postdose (up to 96 hours)
Fraction of Omaveloxolone Excreted in Breast Milk (Fe) Over 24 Hours (Fe0-24)
Time frame: At multiple timepoints postdose (up to 24 hours)
Fraction of Omaveloxolone Excreted in Breast Milk (Fe) Over 96 Hours (Fe0-96)
Time frame: At multiple timepoints postdose (up to 96 hours)
Cmax of Omaveloxolone in Plasma
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Tmax of Omaveloxolone in Plasma
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
AUC[Cav] of Omaveloxolone in Plasma
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
AUC0-tlast of Omaveloxolone in Plasma
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
AUCinf of Omaveloxolone in Plasma
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Terminal Elimination Rate Constant (λz) of Omaveloxolone in Plasma
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Apparent Plasma Terminal Elimination Half-Life (t1/2) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Apparent Plasma Clearance After Extravascular Administration (CL/F) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Apparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Percent of Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC%extrap) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Plasma Unbound Fraction (fu,p) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Cmax of Unbound Plasma Fraction (Cmax,u) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Cav of Unbound Plasma Fraction (AUCinf,u) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
AUC0-tlast of Unbound Plasma Fraction (AUC0-last,u) of Omaveloxolone in Plasma
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
AUCinf of Unbound Plasma Fraction (AUCinf,u) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Estimated Daily Infant Dosage (DID) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Relative Infant Dose (RID) of Omaveloxolone
Time frame: Predose and at multiple timepoints postdose (up to Day 15)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to end of study follow-up (up to 45 days)
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Mar 2025, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omaveloxolone